Molina Healthcare (MOH) Stock Overview
Provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MOH Community Fair Values
Create NarrativeSee what 119 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$411.65
FV
46.1% undervalued intrinsic discount7.42%
Revenue growth p.a.
267
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
Molina Healthcare, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$221.74 |
| 52 Week High | US$244.89 |
| 52 Week Low | US$121.06 |
| Beta | 0.74 |
| 1 Month Change | 12.32% |
| 3 Month Change | 26.93% |
| 1 Year Change | 16.55% |
| 3 Year Change | -28.74% |
| 5 Year Change | -14.44% |
| Change since IPO | 1,563.05% |
Recent News & Updates
Seeking Alpha • Jul 19
Molina Healthcare: The Market Has The Story Backwards
Summary Molina Healthcare is rated Hold as its stock fully prices in a 2027 recovery, with no clear upside or downside at $225. Headline earnings deterioration is driven by non-recurring charges and membership losses, not by underlying cost inflation or operational distress. Medical care ratio trends are favorable and in line with management’s expectations, supporting the credibility of a cyclical recovery rather than structural cost issues. Valuation is stretched on depressed 2026 earnings but normalizes if 2027 EPS rebounds as guided; membership stability and rate adequacy remain key uncertainties. Read the full article on Seeking Alpha
Narrative Update • Jul 15
MOH: Medicaid Margin Recovery And Illinois Contract Win Will Drive 2026 Upside
Analysts have raised their fair value estimate for Molina Healthcare to $286 from $260.28. They cite updated price targets across the sector, slightly lower discount rate assumptions, and model revisions that incorporate modestly higher revenue growth, improved profit margins, and a lower future P/E multiple.
Narrative Update • Jul 01
MOH: Medicaid Rate And Exchange Risks Will Pressure Future Earnings Stability
Molina Healthcare's analyst fair value estimate has been lifted by about $42 to $191.76 per share as analysts factor in updated healthcare services models, a steadier policy backdrop for managed care, and expectations for margin recovery, despite some caution around exchange risk adjustment and rate assumptions. Analyst Commentary Recent research on Molina Healthcare highlights a mix of optimism on the company’s execution and policy backdrop, alongside pointed questions about margin durability, exchange exposure, and rate assumptions.Recent updates
Seeking Alpha • Jul 19
Molina Healthcare: The Market Has The Story Backwards
Summary Molina Healthcare is rated Hold as its stock fully prices in a 2027 recovery, with no clear upside or downside at $225. Headline earnings deterioration is driven by non-recurring charges and membership losses, not by underlying cost inflation or operational distress. Medical care ratio trends are favorable and in line with management’s expectations, supporting the credibility of a cyclical recovery rather than structural cost issues. Valuation is stretched on depressed 2026 earnings but normalizes if 2027 EPS rebounds as guided; membership stability and rate adequacy remain key uncertainties. Read the full article on Seeking AlphaNarrative Update • Jul 15
MOH: Medicaid Margin Recovery And Illinois Contract Win Will Drive 2026 Upside
Analysts have raised their fair value estimate for Molina Healthcare to $286 from $260.28. They cite updated price targets across the sector, slightly lower discount rate assumptions, and model revisions that incorporate modestly higher revenue growth, improved profit margins, and a lower future P/E multiple.Narrative Update • Jul 01
MOH: Medicaid Rate And Exchange Risks Will Pressure Future Earnings Stability
Molina Healthcare's analyst fair value estimate has been lifted by about $42 to $191.76 per share as analysts factor in updated healthcare services models, a steadier policy backdrop for managed care, and expectations for margin recovery, despite some caution around exchange risk adjustment and rate assumptions. Analyst Commentary Recent research on Molina Healthcare highlights a mix of optimism on the company’s execution and policy backdrop, alongside pointed questions about margin durability, exchange exposure, and rate assumptions.Narrative Update • Jun 17
MOH: Medicaid Margin Recovery And Stable Policy Backdrop Will Drive 2026 Upside
Analysts have nudged their fair value estimate for Molina Healthcare to $260.28 from $258.66, citing updated sector models, a more stable policy backdrop for managed care, and company specific margin and utilization trends reflected in a slightly adjusted discount rate, revenue growth outlook, profit margin and forward P/E assumptions. Analyst Commentary Recent commentary on Molina Healthcare highlights a mix of cautious and constructive views.Narrative Update • Jun 03
MOH: Medicaid Margin Normalization Will Support 2026 Earnings Recovery Case
Molina Healthcare's analyst price target has been revised higher to roughly $259 from about $250, with analysts citing stronger managed care sentiment following Q1 reports, improved confidence in Medicaid and Medicare Advantage margin recovery, and more supportive assumptions for revenue growth, profitability, and future P/E multiples. Analyst Commentary Recent research updates point to a more supportive backdrop around Molina Healthcare, with several bullish analysts revising price targets higher and reinforcing confidence in the managed care setup following Q1 results.
Narrative Update • May 19
MOH: Persistent Medicaid Acuity Pressure Will Constrain Future Earnings Quality
Analysts have adjusted the fair value estimate for Molina Healthcare to $129 from $109, reflecting updated assumptions for revenue growth, profit margins, and a higher future P/E multiple that align with recent price target revisions and rating changes across the Street. Analyst Commentary Recent Street research on Molina Healthcare shows a split view, with some firms raising price targets while others reset expectations after recent earnings and guidance updates.Narrative Update • May 03
MOH: Government Program Reset Will Support 2026 Earnings Recovery Case
The analyst fair value estimate for Molina Healthcare has moved from $214.86 to $249.67, as analysts point to updated expectations for revenue growth, improved profit margin assumptions, and a lower future P/E multiple following a series of price target increases and a recent double upgrade to Buy. Analyst Commentary Recent Street research on Molina Healthcare shows a mix of caution and renewed optimism, with several price target revisions clustered around the latest quarterly update and forward guidance.Narrative Update • Apr 17
MOH: Medicaid And Medicare Cost Pressures Will Reshape Future Earnings Stability
Analysts have trimmed their average fair value estimate for Molina Healthcare from $155.69 to $149.76. This reflects reduced revenue growth and profit margin assumptions, even as some firms raise price targets and others cut them in response to recent Q4 results, Medicaid cost pressures and updated Centers for Medicare & Medicaid Services commentary.Narrative Update • Apr 03
MOH: Elevated Medicaid Acuity And Medical Cost Trends Will Pressure Future Earnings
Molina Healthcare's updated fair value estimate has been reduced from $144.00 to $109.00 as analysts recalibrate price targets, which now range from $128 to $180, to reflect concerns about elevated medical cost trends, Medicaid and exchange acuity pressures, and a reset earnings outlook following a weaker Q4 and revised 2026 guidance. Analyst Commentary Recent Street research on Molina Healthcare reflects a shift toward more cautious views, with a cluster of reduced price targets and a key downgrade following the latest Q4 results and updated 2026 guidance.Narrative Update • Mar 19
MOH: Government Program Reset Will Set Up 2026 Earnings Recovery Potential
Narrative Update Analysts have broadly reduced their price targets on Molina Healthcare, with the updated fair value estimate moving from about $244 to about $215 as they factor in higher medical cost trend pressure, lower 2026 and 2027 earnings expectations, and a reset in projected profitability and future P/E multiples. Analyst Commentary Recent research on Molina Healthcare highlights a reset in expectations after the Q4 earnings miss and updated 2026 guidance, with several firms lowering price targets and adjusting earnings models.Narrative Update • Mar 05
MOH: Medicaid And Medicare Pressures Will Shape Future Earnings Power
Narrative Update The analyst price target for Molina Healthcare has been cut by about $31 to $155.69, as analysts reset expectations after a Q4 earnings miss, lower 2026 EPS guidance and increased concerns around Medicaid and Medicare pressure, revenue and expense volatility, and whether the new long term earnings floor is sufficiently conservative, while also reflecting a higher assumed future P/E multiple. Analyst Commentary Recent research around Molina Healthcare reflects a clear reset in expectations following the Q4 earnings miss and updated 2026 outlook.Narrative Update • Feb 19
MOH: Government Program Positioning Will Drive Future Earnings Repricing Potential
Our updated narrative trims Molina Healthcare's fair value estimate from $263.81 to $244.11. This reflects a wave of analyst price target cuts into the $142 to $220 range as models incorporate Q4 results, 2026 guidance, and added Medicaid and Medicare pressure.Analysis Article • Feb 11
Molina Healthcare, Inc. (NYSE:MOH) Might Not Be As Mispriced As It Looks After Plunging 31%
Molina Healthcare, Inc. ( NYSE:MOH ) shares have had a horrible month, losing 31% after a relatively good period...Narrative Update • Feb 05
MOH: Florida CMS Win And Policy Shifts Will Shape Future Earnings Power
Our updated narrative reflects a higher implied analyst price target for Molina Healthcare, moving from about US$170 to roughly US$187 per share, as analysts factor in recent target increases from multiple firms, expectations around Medicare Advantage and Medicaid trends, and the potential earnings tailwind from new contract wins such as the Florida CMS selection. Analyst Commentary Recent research on Molina Healthcare splits into two broad camps, with some analysts focusing on earnings upside from contracts and product mix, and others flagging policy and rate headwinds across managed care.Narrative Update • Jan 22
MOH: Government Managed Care Awards Will Support Future Earnings Repricing
Analysts have nudged their fair value estimate for Molina Healthcare higher from about $251.88 to roughly $263.81, citing slightly firmer margin assumptions, modestly stronger revenue growth expectations, and a lower assumed future P/E multiple, alongside recent price target revisions across the managed care peer group. Analyst Commentary Recent Street commentary on Molina Healthcare has been mixed, but there is a clear group of bullish analysts who see room for upside if execution on margins and growth targets stays on track.Narrative Update • Jan 07
MOH: Government Managed Care Contracts Will Drive Future Earnings Repricing
Analysts have reset their price targets on Molina Healthcare, with our fair value estimate moving from US$279.05 to US$251.88 as they factor in tighter profit margin expectations, a slightly higher discount rate, and a higher future P/E multiple supported by mixed, but generally constructive, research on Medicare Advantage and Medicaid exposure. Analyst Commentary Recent Street commentary on Molina Healthcare reflects a split view, with some firms trimming expectations after Q3 while others see room for recovery in government managed care, particularly around Medicare Advantage and Medicaid valuations.Narrative Update • Dec 16
MOH: Medicaid Margin Pressure Will Drive Earnings Risk Despite Florida Contract Tailwind
We lower our fair value estimate for Molina Healthcare to $144 from $153 per share as analysts trim price targets in response to Q3 earnings misses, rising medical cost and Medicaid margin pressure, and more conservative assumptions for 2025 to 2026 profitability, despite selective tailwinds such as the Florida CMS award. Analyst Commentary Bearish analysts have turned more cautious on Molina Healthcare following the Q3 earnings miss, multiple guidance cuts since mid year, and subdued commentary around the earnings trajectory into 2026.Narrative Update • Dec 01
MOH: Florida Win Will Drive 5% EPS Gain Amid Medicaid Uncertainty
Molina Healthcare's analyst price target has been revised downward to $170 from $172.53. Analysts cite ongoing medical cost pressures and a cautious Medicaid outlook as primary drivers for the reduction.Narrative Update • Nov 17
MOH: Florida Contract Win Will Drive Medicaid Earnings Opportunity Into 2025
Molina Healthcare’s analyst price target has declined from approximately $179 to $173 per share. Analysts cite persistent medical cost pressures and cautious outlooks on Medicaid margins as key drivers behind the recalibration.Analysis Article • Nov 04
Positive Sentiment Still Eludes Molina Healthcare, Inc. (NYSE:MOH) Following 27% Share Price Slump
Molina Healthcare, Inc. ( NYSE:MOH ) shares have had a horrible month, losing 27% after a relatively good period...Narrative Update • Nov 03
MOH: Margin Recovery Will Rely On Navigating Medicaid Headwinds And ACA Premium Hikes
Molina Healthcare's analyst price target has been revised downward from approximately $198 to $179 per share. Analysts cite lower earnings forecasts and ongoing uncertainty in Medicaid and state-level healthcare funding as key drivers of the adjustment.Narrative Update • Oct 20
Winning RFPs And Medicaid Adjustments Will Secure Future Healthcare Success
Analysts have modestly increased their price target for Molina Healthcare to approximately $198, citing industry-wide optimism about core demand drivers and regulatory clarity. This comes despite concerns over margin pressure and a challenging operating environment.Narrative Update • Oct 06
Winning RFPs And Medicaid Adjustments Will Secure Future Healthcare Success
Molina Healthcare's analyst price target has decreased from $202.43 to $189.43. Analysts cite growing industry cost pressures, challenging 2026 Star plan benchmarks, and dampened near-term earnings visibility across managed care companies as key reasons for this revision.Narrative Update • Sep 21
Winning RFPs And Medicaid Adjustments Will Secure Future Healthcare Success
Despite increased implementation and margin risks tied to stricter CMS Star ratings, sector cost trends, and uncertain legislative impacts, analysts have modestly raised their fair value estimate for Molina Healthcare from $196.71 to $202.43. Analyst Commentary Stricter CMS Star rating cut points for 2026 are expected to challenge managed care organizations' ability to maintain high-rated plans, potentially impacting payment and competitiveness.Narrative Update • Sep 06
Winning RFPs And Medicaid Adjustments Will Secure Future Healthcare Success
Analysts have revised their outlook on Molina Healthcare to a more cautious stance due to higher-than-expected cost trends, expense pressures, and regulatory uncertainties impacting earnings visibility and risk pool quality, resulting in a lowered consensus price target from $201.36 to $196.71. Analyst Commentary Bearish analysts cite higher-than-expected cost trends and broad-based expense pressures within managed care and exchange businesses, leading to lower earnings visibility for Molina Healthcare.Analysis Article • Jul 27
Molina Healthcare (NYSE:MOH) Is Reinvesting At Lower Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Seeking Alpha • Nov 13
Analyzing And Valuing Molina Healthcare As A Solid Company
Summary Molina Healthcare increased its Medicaid membership by 49.55% between 2019 and 2023. The Medicaid health program, which represents 91% of Molina Healthcare’s revenues, is expected to grow 5.2% annually between 2023 and 2032. After valuing the company using the DCF model, the company is undervalued by 82.37% in the baseline scenario, and is undervalued by 3.02% in the pessimistic scenario. Read the full article on Seeking AlphaShareholder Returns
| MOH | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -5.0% | 0.7% | -0.7% |
| 1Y | 16.6% | 40.6% | 17.3% |
Return vs Industry: MOH underperformed the US Healthcare industry which returned 40.6% over the past year.
Return vs Market: MOH matched the US Market which returned 17.3% over the past year.
Price Volatility
| MOH volatility | |
|---|---|
| MOH Average Weekly Movement | 7.0% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MOH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MOH's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 19,000 | Joe Zubretsky | www.molinahealthcare.com |
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces in the United States. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company was founded in 1980 and is headquartered in Long Beach, California.
Molina Healthcare, Inc. Fundamentals Summary
| MOH fundamental statistics | |
|---|---|
| Market cap | US$11.80b |
| Earnings (TTM) | US$188.00m |
| Revenue (TTM) | US$43.10b |
61.4x
P/E Ratio0.3x
P/S RatioIs MOH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOH income statement (TTM) | |
|---|---|
| Revenue | US$43.10b |
| Cost of Revenue | US$39.28b |
| Gross Profit | US$3.82b |
| Other Expenses | US$3.63b |
| Earnings | US$188.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 23, 2026
| Earnings per share (EPS) | 3.61 |
| Gross Margin | 8.86% |
| Net Profit Margin | 0.44% |
| Debt/Equity Ratio | 92.3% |
How did MOH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 21:47 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molina Healthcare, Inc. is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hua Ha | Baird |
| Joshua Raskin | Barclays |
| Andrew Mok | Barclays |